论文部分内容阅读
目的:头孢哌酮钠舒巴坦钠与阿奇霉素联合应用对大叶性肺炎病人体内TNF-α、IL-6及HMGB1的变化影响及其临床疗效研究。方法:收集2012年11月至2015年3月期间到笔者所在医院就诊并诊断患有大叶性肺炎的病人随机平分成两组,其中A组与B组成员分别使用头孢哌酮钠舒巴坦钠+阿奇霉素和仅使用阿奇霉素进行大叶性肺炎对症治疗。通过炎性指标变化情况及对肺功能、不良反应的观察,分析两种药物联合应用对大叶性肺炎病人体内TNF-α、IL-6及HMGB1的变化影响和临床应用价值。结果:A组经联合用药治疗后相关炎症指标改善情况普遍优于B组;A组大叶性肺炎病人咳嗽、啰音及相关体征表现恢复速度快于B组,且A组病人在联合药物治疗后FEF和FEF50指标上的改善情况更为突出;而A组病人不良反应发生种类及例数、比率与B组却相差不大(P>0.05)。结论:头孢哌酮钠舒巴坦钠与阿奇霉素的联合应用可有效降低病人体内TNF-α、IL-6及HMGB1浓度水平,且其治疗效果较为突出,具有一定的应用价值。
OBJECTIVE: To investigate the effects of cefoperazone sodium and sulbactam sodium combined with azithromycin on the changes of TNF-α, IL-6 and HMGB1 in patients with lobar pneumonia and its clinical efficacy. Methods: From November 2012 to March 2015, the patients who visited the author’s hospital and diagnosed with lobar pneumonia were randomly divided into two groups. The patients in group A and group B were treated with cefoperazone sodium and sulbactam sodium and azithromycin And only azithromycin for lobar pneumonia symptomatic treatment. Through the change of inflammatory index and the observation of lung function and adverse reaction, the influence of two drugs on the changes of TNF-α, IL-6 and HMGB1 in patients with lobar pneumonia and the clinical value were analyzed. Results: The improvement of inflammation index in group A was better than that in group B after treatment with combination therapy. In group A, the recovery of cough, rales and related signs was faster in group A than in group B, and the patients in group A were treated with combination therapy After FEF and FEF50 indicators of the improvement is more prominent; and A group of patients with adverse reactions and the number of cases, the ratio was not significantly different from the B group (P> 0.05). Conclusion: The combination of cefoperazone sodium and sulbactam sodium with azithromycin can effectively reduce the level of TNF-α, IL-6 and HMGB1 in patients, and its therapeutic effect is more prominent, which has a certain value.